Affiliation:
1. Shandong University
2. New Sunshine Charity Foundation
Abstract
Abstract
Purpose The caregivers of adult patients with β-thalassemia major bear not only physical but also emotional and economic pressures of providing care. The aim of this study was to examine the determinants of caregiver burden in adult patients with β-thalassemia major in mainland China.
Methods In this cross-sectional study, we conducted an online survey with snowball sampling covering seven provinces between September 1, 2021, and January 31, 2022, of patients aged ≥18 years with β-thalassemia major and their caregivers. Caregiver burden was assessed using the Zarit Burden Interview (ZBI). Data on patient demographics, disease and therapy characteristics, and caregivers’ demographic characteristics were collected and analyzed using independent t-tests, analysis of variance, and multiple linear regression.
Results Of 75 included patients, more than half (50.7%) were male. The mean patient age was 24.69±5.59 years. The mean age of the caregivers was 50.60±9.16 years, with women (74.7%) being predominant. The ZBI score was 38.00 ±17.02. Multiple linear regression analysis showed that patients with interrupted blood transfusion therapy and caregivers required to care of others were positively associated with caregiver burden (p<0.05). Married caregivers were negatively associated with caregiver burden (p<0.05).
Conclusions The caregivers of adult patients with β-thalassemia major in mainland China experienced a moderate-to-severe level of caregiving burden. The burden was higher in patients with a history of interrupted blood transfusion therapy or in caregivers caring for others. Additionally, married caregivers experienced lower burdens compared to non-married caregivers. These findings provide a reference to identify caregivers with higher burdens among patients with β-thalassemia major.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy;Senol SP;J Basic Clin Pharm,2016
2. Taher AT, Weatherall DJ, Cappellini MD, Thalassaemia. Lancet. 2018;391:155–67.
3. A cost-of-illness analysis of β-Thalassaemia major in children in Sri Lanka - experience from a tertiary level teaching hospital;Reed-Embleton H;BMC Pediatr,2020
4. Liu Y, Fang J. Interpretation of guidelines for diagnosis and treatment of beta-thalassemia major (2017). Chin J Practical Pediatr. 2018.
5. Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders;Colah R;Expert Rev Hematol,2010